Benjamin Herzberg, MD, discusses the management challenges associated with STK11/KEAP1-mutated tumors, SMARCA4-deficient undifferentiated tumors, and NUT carcinoma.
Benjamin Herzberg, MD
Advertisement
Benjamin Herzberg, MD, is an assistant professor of medicine at Columbia University Medical Center and an oncologist at Herbert Irving Comprehensive Cancer Center in New York, New York
Articles by Benjamin Herzberg, MD
Benjamin Herzberg, MD, discusses unanswered questions regarding the role of KRAS inhibitors for patients with non–small cell lung cancer.
Benjamin Herzberg, MD the clinical similarities and key distinctions between sotorasib and adagrasib for KRAS G12C+ NSCLC.
Benjamin Herzberg, MD, discusses current and future research efforts in KRAS-mutated NSCLC.
Experts from across oncology specialties discuss the long-term effects of the COVID-19 pandemic on patient care.
The Herbert Irving Comprehensive Cancer Center has developed processes to actively screen any patient with a relevant mutation for an open trial.
Advertisement
Latest Updated Articles
Moving From Passive to Active Clinical Trials EnrollmentPublished: January 29th 2024 | Updated:
Dr Herzberg on Notable Ongoing Research in KRAS-Mutated NSCLCPublished: April 2nd 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5